Ask AI
ProCE Banner Activity

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer

Slideset

Downloadable slideset from Komal Jhaveri, MD, FACP, on the role of TROP-2‒directed antibody‒drug conjugates in the therapeutic landscape for patients with HER2-negative advanced breast cancer, including HER2-low disease.

Released: February 22, 2024

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.